Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2008

View Archived Issues

Novel oncolytic MP-529 shows activity in vivo

Lodamin formulation allows oral administration of the antiangiogenic TNP-470

Higher immunogenicity for novel quadrivalent meningoccocal vaccine in phase III study

Recent patent literature discloses new treatment options for cancer

Inhibition of gap junction signaling protects retinal cells against ischemia-induced apoptosis

Spotlight on ranibizumab phase III trials for AMD

Regeneron's angiopoietin-2 neutralizing antibody promotes CNV regression

NicOx initiates first phase I study for nitric oxide-donating agent in hypertension

Pharmexa stops one of two phase III trials for GV-1001

Starpharma presents positive VivaGel clinical study results

SpectRx changes name to Guided Therapeutics

Orion discontinues development of new COMT inhibitor for Parkinson's disease

FDA delays issuing of action letter on Adolor's NDA for Entereg in postoperative ileus

Roche reports results from LITHE phase III trial of Actemra in RA

FDA grants priority review of Gamunex as treatment for neurological disorder CIDP

Recent Astellas patent describes new compounds for treating urinary incontinence

NIH awards grant to LIAI grant to test anti-H3 antibody treatment against smallpox

New antibacterial agents reported in recent LEK and LICA patents

Savient reports positive interim data from open-label extension to phase III trials of Puricase

Oxford BioMedica presented update

Novelos presents positive results in ongoing phase II neoadjuvant breast cancer trial

Proellex shows no adverse cardiac effects in a pilot trial

Argos initiates phase II proof-of-concept trial for AGS-004 in HIV

ImmuPharma received approval for IPP-201101 trademark Lupuzor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...